Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial
作者
Ulrich Specks,Peter A. Merkel,Gary S. Hoffman,Carol A. Langford,Robert Spiera,Philip Seo,Cees G. M. Kallenberg,E. William St. Clair,Linna Ding,Lisa Webber,Masoud Mokhtarani,Nadia K. Tchao,Peter H. Sayre,Vicky Seyfert-Margolis,David Iklé,Paul Brunetta P,David Zhang,Lourdes P. Sejismundo,Mark Mueller,John H. Stone
出处
期刊:The Open Arthritis Journal [Bentham Science] 日期:2011-11-16卷期号:4: 1-18被引量:20
Granulomatosis with polyangiitis (formerly Wegener's) (GPA) and microscopic polyangiitis (MPA) share many clinical and pathological features, including antineutrophil cytoplasmic antibodies (ANCA) directed against either proteinase 3 (PR3) or myeloperoxidase (MPO). These two "ANCA-associated" vasculitides (AAV) are associated with a high mortality in untreated patients, substantial morbidity from standard therapies, and a significant risk of disease relapse.